(News Bulletin 247) – Nicox rose almost 10% on Wednesday on the Paris Stock Exchange following the presentation of new data on two of its compounds.
The ophthalmology specialist reports that non-clinical work on his NCX 470 eye drops has provided ‘convincing’ new evidence of the product’s protective activity on retinal cells, in addition to its ability to reduce intraocular pressure (IOP ).
NCX 470, a novel nitric oxide-donating bimatoprost eye drop, is currently in Phase 3 clinical development for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
At the same time, data on NCX 1728 indicate that stimulation of the soluble nitric oxide/guanylyl cyclase signaling pathway is the major contributor to these effects.
According to Nicox, these data mean that NCX 1728 may show promise in the treatment of retinopathies in which ocular perfusion dysfunction and neovascularization are key pathophysiological features in disease progression.
These data were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) currently being held in New Orleans, Louisiana.
Note that the transfer of the listing of securities from the regulated market of Euronext Paris (compartment C) to the multilateral trading system Euronext Growth Paris will be effective from Friday.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
